Abstract
Castration-resistant prostate cancer (CRPC) is an advanced subtype of prostate cancer with limited therapeutic options. Here, we applied a systems-based modeling approach called kinome regularization (KiR) to identify multitargeted kinase inhibitors (KIs) that abrogate CRPC growth. Two predicted KIs, PP121 and SC-1, suppressed CRPC growth in two-dimensional in vitro experiments and in vivo subcutaneous xenografts. An ex vivo bone mimetic environment and in vivo tibia xenografts revealed resistance to these KIs in bone. Combining PP121 or SC-1 with docetaxel, standard-of-care chemotherapy for late-stage CRPC, significantly reduced tibia tumor growth in vivo, decreased growth factor signaling, and vastly extended overall survival, compared to either docetaxel monotherapy. These results highlight the utility of computational modeling in forming physiologically relevant predictions and provide evidence for the role of multitargeted KIs as chemosensitizers for late-stage, metastatic CRPC.
Original language | English (US) |
---|---|
Article number | e2103623118 |
Journal | Proceedings of the National Academy of Sciences of the United States of America |
Volume | 118 |
Issue number | 40 |
DOIs | |
State | Published - Oct 5 2021 |
Keywords
- Combination therapy
- Computational modeling
- Kinase
- Prostate cancer
ASJC Scopus subject areas
- General
MD Anderson CCSG core facilities
- Advanced Technology Genomics Core
- Cytogenetics and Cell Authentication Core
- Research Animal Support Facility
- Functional Proteomics Reverse Phase Protein Array Core
- Bioinformatics Shared Resource